-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Wt+c6P6+kwp9EIUeax9ThYJneZNJTAFxNsOLIwYtBRwMCaptu+/vQbr0XjI9AVax BoUhHGnkbvzofpIRZUCtaA== 0000950134-04-003377.txt : 20040312 0000950134-04-003377.hdr.sgml : 20040312 20040312130654 ACCESSION NUMBER: 0000950134-04-003377 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20040311 ITEM INFORMATION: Financial statements and exhibits ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20040312 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LIFECORE BIOMEDICAL INC CENTRAL INDEX KEY: 0000028626 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 410948334 STATE OF INCORPORATION: MN FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-04136 FILM NUMBER: 04665280 BUSINESS ADDRESS: STREET 1: 3515 LYMAN BLVD CITY: CHASKA STATE: MN ZIP: 55318-3051 BUSINESS PHONE: 6123684300 FORMER COMPANY: FORMER CONFORMED NAME: DIAGNOSTIC INC DATE OF NAME CHANGE: 19861214 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN MEDICAL RESEARCH INC DATE OF NAME CHANGE: 19691118 8-K 1 c83737e8vk.htm FORM 8-K e8vk
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):March 11, 2004

 
Lifecore Biomedical, Inc.
(Exact name of Registrant as specified in its charter)
         
Minnesota   O-4136   41-0948334
 
 
(State or other jurisdiction of
incorporation or organization)		   (Commission File Number)   (IRS Employer Identification No.)
         
3515 Lyman Boulevard
Chaska, Minnesota		       55318  
     
 
(Address of principal executive offices)       (Zip Code)

Registrant’s telephone number, including area code: 952-368-4300

 

Item 7. Financial Statements and Exhibits
Item 9. Regulation FD Disclosure
SIGNATURE
Press Release

Table of Contents

Item 7. Financial Statements and Exhibits

(c)  The following exhibit is being furnished herewith:

  99.1    Press release dated March 11, 2004

Item 9. Regulation FD Disclosure

On March 11, 2004 Lifecore Biomedical, Inc. (“Lifecore”) issued a press release which announced today that Larry Hiebert has been appointed Vice President of Operations and David Noel has been appointed Vice President of Finance and Chief Financial Officer.

A copy of Lifecore’s press release is attached hereto as Exhibit (99.1) and hereby incorporated by reference.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
        LIFECORE BIOMEDICAL, INC.
 
Dated:   March 11, 2004   /w/ Dennis J. Allingham
Dennis J. Allingham
Chief Executive Officer and President

 

Table of Contents

Exhibit Index

     
99.1   Press release dated March 11, 2004

  EX-99.1 3 c83737exv99w1.htm PRESS RELEASE exv99w1

 

Exhibit 99.1

LIFECORE NAMES OFFICERS

Chaska, MN. March 11, 2004 — LIFECORE BIOMEDICAL, INC. (NASDAQ:LCBM) announced today that Larry Hiebert has been appointed Vice President of Operations and David Noel has been appointed Vice President of Finance and Chief Financial Officer.

“The promotions of Larry and Dave recognize their respective contributions to our company,” said Dennis J. Allingham, Lifecore’s President and CEO. “These actions strengthen our management team and enhance our ability to execute key operating objectives, while permitting us to focus upon the strategic development of our business.”

Mr. Hiebert has been the Director of Operations since 1996. He has held various manufacturing and materials management positions within the company since 1983.

Mr. Noel, a Certified Public Accountant, has served as the company’s Controller for the past two years. Prior to joining Lifecore, Noel held senior financial management positions. His background includes a broad range of experience in public accounting, manufacturing and medical products industries.

About Lifecore Biomedical

Lifecore Biomedical develops, manufactures, and markets biomaterials and medical devices for use in various surgical markets through two divisions, Hyaluronan Division and Oral Restorative Division. The Hyaluronan Division conducts its business through OEM and contract manufacturing alliances in the gynecologic, ophthalmic, orthopedic, and veterinary surgical fields. The Oral Restorative Division conducts its dental surgery business through direct sales and marketing in the United States, Germany, Italy, and Sweden, and through 23 distributors in 35 countries.

Forward-Looking Statements

Certain statements in this release are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including the statements regarding execution of key operating objectives and strategic development of the business. Such forward-looking statements involve numerous risks and uncertainties in the complex regulatory and competitive aspects of Lifecore’s business activity that could cause actual results to differ materially from those implied. Investors are strongly cautioned to review more detailed discussions of those risks presented in the Company’s filings with the Securities and Exchange Commission including Exhibit 99.1 to Lifecore’s annual report on Form 10-K for the fiscal year ending June 30, 2003.

Additional general corporate information is available on the internet at http://www.lifecore.com.
Contact 952-368-4300
Dennis J. Allingham, President and CEO

- END -

  -----END PRIVACY-ENHANCED MESSAGE-----